Skip to main content

Stephen Greene

Associate Professor of Medicine
Medicine, Cardiology

Overview


I am a cardiologist with a clinical and research interest in heart failure. I take care of patients with various types of heart failure, including patients who are best treated with medications and patients who receive advanced therapies like heart transplantation and mechanical assist devices. I became a heart failure cardiologist to help patients manage their heart conditions and best achieve their goals for their health. I am strongly committed to helping patients thoroughly understand their medical conditions and helping them make informed medical decisions aligned with their preferences.

My research interests are focused on strategies and therapies to improve outcomes and quality of life for patients with heart failure. This involves research through clinical trials and through examining data from real-world clinical practice. Below, you will find my specific research interests:

  • Use and dosing of evidence-based heart failure medications
  • Management of worsening heart failure outside the hospital
  • Novel pharmacological and non-pharmacological approaches to heart failure
  • Improving outcomes following a hospitalization for heart failure
  • Surrogate and nonfatal endpoints in heart failure clinical trials
  • Clinical trial design and operations
  • Improving site-based heart failure research

Current Appointments & Affiliations


Associate Professor of Medicine · 2024 - Present Medicine, Cardiology, Medicine
Member in the Duke Clinical Research Institute · 2020 - Present Duke Clinical Research Institute, Institutes and Centers

Recent Publications


Clinical Course and Outcomes of Acute Heart Failure With Moderate-to-Severe Mitral or Tricuspid Regurgitation.

Journal Article Am J Cardiol · March 1, 2025 Moderate-to-severe mitral regurgitation (MR) and tricuspid regurgitation (TR) are common in patients hospitalized with heart failure (HF) and have been associated with poor quality of life and increased mortality. The impact of these valve lesions on in-ho ... Full text Link to item Cite

Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: The TRANSFORM-HF trial.

Journal Article Eur J Heart Fail · February 2025 AIMS: The TRANSFORM-HF trial found no difference in clinical outcomes between torsemide versus furosemide after hospitalization for heart failure. This analysis aimed to assess the impact of diuretic dosing on the primary and secondary clinical outcomes. M ... Full text Link to item Cite

Initiation and sequencing of guideline-directed medical therapy for heart failure across the ejection fraction spectrum.

Journal Article Heart Fail Rev · January 15, 2025 Strong evidence supports the importance of rapid sequence or simultaneous initiation of quadruple guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) for substantially reducing risk of mortality and hospitaliz ... Full text Link to item Cite
View All Publications

Recent Grants


Otsuka HF Ph2 POC

Clinical TrialPrincipal Investigator · Awarded by Otsuka Pharmaceutical Development & Commercialization, Inc. · 2024 - 2027

PARACOR-19

Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2021 - 2026

Identifying barriers to and optiMizing in-hosPitaL usE of evidenced-based Medical thErapies for patieNTs with Cardio-Renal-Metabolic Disease (IMPLEMENT-CRM)

Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2023 - 2026

View All Grants

Education, Training & Certifications


Northwestern University, Feinberg School of Medicine · 2012 M.D.